礼来公布Omvoh一年期事后分析阳性数据并定档Q3财报，但为非关键性post-hoc数据，难撼万亿市值

On Thursday, Eli Lilly and Company (LLY), a pharmaceutical company, reported new one-year data showing that patients treated with Omvoh (mirikizumab-mrkz) achieved comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease.
Company Profile
Lilly develops medicines across several therapeutic areas, including diabetes, obesity, immunology and oncology. Omvoh is an interleukin-23p19 (IL-23p19) antagonist approved for adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease.
Omvoh Clinical Data HighlightsIn a post-hoc analysis of the Phase 3 LUCENT-2 study, 27.7% of Omvoh-treated patients with UC achieved comprehensive disease control at one year, compared with 14% of patients receiving placebo. The composite outcome included clinical remission, histologic remission, normalized inflammatory biomarkers and no corticosteroid use.
Among patients with prior biologic treatment failure, 23.4% of Omvoh-treated patients achieved comprehensive disease control, compared with 9.4% receiving placebo.
In the Phase 3 VIVID-1 study of Crohn's disease, 20.4% of patients treated with Omvoh achieved corticosteroid-free deep remission at one year, compared with 2% receiving placebo. This outcome combined clinical remission, endoscopic remission and no corticosteroid use.
Among patients with prior biologic treatment failure, 15.7% of Omvoh-treated patients achieved corticosteroid-free deep remission, compared with none of those receiving placebo.
Patient-Reported Outcomes
The analyses also found that patients achieving these composite outcomes were more likely to report improvements in health-related quality of life.
Among Omvoh-treated UC patients who achieved comprehensive disease control, 91.1% also achieved remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), compared with 65.2% of those who did not achieve the composite outcome.
In Crohn's disease, 88.1% of patients achieving corticosteroid-free deep remission also achieved IBDQ remission, compared with 51% of those who did not achieve deep remission.
Patients with UC who achieved comprehensive disease control were also more likely to report minimal or no bowel urgency and greater improvements in work productivity.
The post-hoc analyses will be presented at United European Gastroenterology (UEG) Week 2026. The safety findings from the LUCENT and VIVID Phase 3 programs have been reported previously.
Third-Quarter 2026 Results
Separately, Lilly announced that it will release its third-quarter 2026 financial results on October 29, 2026.
Outlook
Lilly continues to evaluate Omvoh in additional treatment approaches, including combination studies in UC and Crohn's disease, as well as ongoing studies in pediatric patients.
The latest analyses support the evaluation of multidimensional treatment goals that combine symptom control, objective measures of inflammation and quality of life. The findings are based on post-hoc analyses of clinical trial data and do not establish that all patients will achieve these outcomes.
LLY is trading up 4.70% at $1,265.56.
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.